Press Release

December 21, 2021
1 min read

Melanoma specialist named ASCO’s 2023-2024 president


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Lynn M. Schuchter, MD, FASCO, has been elected ASCO president for the 2023-2024 term.

Schuchter, chief of the division of hematology-oncology at Perelman School of Medicine at University of Pennsylvania, will serve a 1-year term as president-elect beginning in June 2022. She will assume the ASCO presidency in June 2023.

Lynn M. Schuchter, MD, FASCO
Lynn Schuchter

“It is a privilege and honor to have the opportunity to lead and partner with my colleagues as ASCO president,” Schuchter said in a press release. “We have much to celebrate due to the dedicated efforts of our colleagues who work each day in the clinic, in hospitals, and through research efforts to improve the lives of people with cancer and prevent more people from developing cancer. Together, in the coming years, we are prepared to make new strides in areas like cancer care equity, improving access to care, the rapid dissemination and application of new knowledge and treatments, and innovating to deliver the best possible care to more patients in more ways and settings than ever before.”

Schuchter, recognized for her expertise in melanoma, also serves as director of Tara Miller Melanoma Center at Abramson Cancer Center. She has served as chief of Penn’s division of hematology-oncology for 15 years.